Utilizing a Simple Method for Stoichiometric Protein Labeling to Quantify Antibody Blockade

[1]  Alan Bensky,et al.  Technologies and applications , 2019, Short-range Wireless Communication.

[2]  K. Wood,et al.  Real-Time Ligand Binding of Fluorescent VEGF-A Isoforms that Discriminate between VEGFR2 and NRP1 in Living Cells , 2018, Cell chemical biology.

[3]  S. Hill,et al.  Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2 , 2018, International journal of molecular sciences.

[4]  Leigh A. Stoddart,et al.  NanoBRET Approaches to Study Ligand Binding to GPCRs and RTKs. , 2017, Trends in pharmacological sciences.

[5]  M. Tabrizi,et al.  Development of Antibody-Based Therapeutics , 2018, Springer Singapore.

[6]  Ningshao Xia,et al.  Molecular and functional analysis of monoclonal antibodies in support of biologics development , 2017, Protein & Cell.

[7]  K. Wood,et al.  Real-time analysis of the binding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes , 2017, Biochemical pharmacology.

[8]  Matthew B Francis,et al.  Targeting the N terminus for site-selective protein modification. , 2017, Nature chemical biology.

[9]  R. Ferris,et al.  Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients , 2016, Clinical Cancer Research.

[10]  K. Wood,et al.  NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions. , 2015, ACS chemical biology.

[11]  S. Hill,et al.  Effects of receptor tyrosine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2 , 2015, British journal of pharmacology.

[12]  Alison J. Smith.  New Horizons in Therapeutic Antibody Discovery , 2015, Journal of biomolecular screening.

[13]  C. Burns,et al.  Applications of cell-based bioassays measuring the induced expression of endogenous genes. , 2014, Bioanalysis.

[14]  E. Breukink,et al.  Site-specific functionalization of proteins and their applications to therapeutic antibodies , 2014, Computational and structural biotechnology journal.

[15]  J. Chin,et al.  Bioorthogonal reactions for labeling proteins. , 2014, ACS chemical biology.

[16]  Xiaoyan Chen,et al.  Platelet-derived growth factors and their receptors: structural and functional perspectives. , 2013, Biochimica et biophysica acta.

[17]  E. Rosenthal,et al.  Preclinical Comparison of Near-Infrared-Labeled Cetuximab and Panitumumab for Optical Imaging of Head and Neck Squamous Cell Carcinoma , 2013, Molecular Imaging and Biology.

[18]  Christopher P. Toseland,et al.  Fluorescent labeling and modification of proteins , 2013, Journal of chemical biology.

[19]  Marjeta Urh,et al.  Development of a Dehalogenase-Based Protein Fusion Tag Capable of Rapid, Selective and Covalent Attachment to Customizable Ligands , 2012, Current chemical genomics.

[20]  Brock F. Binkowski,et al.  Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate , 2012, ACS chemical biology.

[21]  G. Yancopoulos,et al.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.

[22]  T. Muir,et al.  Genetically encoded 1,2-aminothiols facilitate rapid and site-specific protein labeling via a bio-orthogonal cyanobenzothiazole condensation. , 2011, Journal of the American Chemical Society.

[23]  K. Wood,et al.  HaloTag-based purification of functional human kinases from mammalian cells. , 2011, Protein expression and purification.

[24]  G. MacBeath,et al.  High- and Low-Affinity Epidermal Growth Factor Receptor-Ligand Interactions Activate Distinct Signaling Pathways , 2011, PloS one.

[25]  Kai Johnsson,et al.  How to obtain labeled proteins and what to do with them. , 2010, Current opinion in biotechnology.

[26]  Thomas D. Pollard,et al.  A Guide to Simple and Informative Binding Assays , 2010, Molecular biology of the cell.

[27]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[28]  H. Prado,et al.  Advances and Applications , 2010 .

[29]  J. Rao,et al.  A biocompatible condensation reaction for the labeling of terminal cysteine residues on proteins. , 2009, Angewandte Chemie.

[30]  F. De Vita,et al.  Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy , 2009, Clinical and experimental immunology.

[31]  E. Trinquet,et al.  HTRF: A Technology Tailored for Drug Discovery –A Review of Theoretical Aspects and Recent Applications , 2009, Current chemical genomics.

[32]  Francisco Ciruela,et al.  Fluorescence-based methods in the study of protein-protein interactions in living cells. , 2008, Current opinion in biotechnology.

[33]  Marjeta Urh,et al.  HaloTag: a novel protein labeling technology for cell imaging and protein analysis. , 2008, ACS chemical biology.

[34]  Michael Höpfner,et al.  Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. , 2008, World journal of gastroenterology.

[35]  Timothy L. Foley,et al.  Site-specific protein modification: advances and applications. , 2007, Current opinion in chemical biology.

[36]  Rainer Bischoff,et al.  Receptor-ligand binding assays: technologies and applications. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[37]  L. Fretto,et al.  Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor. , 1993, Journal of Biological Chemistry.

[38]  M. Brinkley.  A brief survey of methods for preparing protein conjugates with dyes, haptens, and cross-linking reagents. , 1992, Bioconjugate chemistry.

[39]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.